Search Medical Condition
Please enter condition
Please choose location

Myrtle Beach, South Carolina Clinical Trials

A listing of Myrtle Beach, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (59) clinical trials

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

This is a phase 2 clinical trial of Seviteronel (an oral, potent and lyase-selective CYP17 inhibitor) in men with castration-resistant prostate cancer (CRPC) progressing on enzalutamide or abiraterone. Approximately 197 subjects will be used to assess treatment efficacy. The study will be conducted in two different clinical cohorts separated by ...

Phase

0.0 miles

Learn More »

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Bladder cancer is the 6th most common cancer in the United States, affecting more men than women. The usual first treatment for NMIBC (Ta, T1, and CIS) is transurethral resection of the bladder tumors followed by intravesical immunotherapy, most commonly with bacillus Calmette-Guérin (BCG). Because of the high risk for ...

Phase

0.0 miles

Learn More »

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

This is a Phase 1/2 study of seviteronel in subjects with castration-resistant prostate cancer (CRPC). Phase 1 was a dose-escalation study enrolling subjects with CRPC that were either "treatment naïve" (not treated with previous abiraterone or enzalutamide), or treated with one or more of the following: abiraterone, enzalutamide, or chemotherapy. ...

Phase

0.0 miles

Learn More »

An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer

This is a multicenter, open-label study (participants will know the identity of study drugs administered) to evaluate the efficacy and safety of JNJ-42756493 in participants with urothelial cancer. The study comprises a 30-days Screening Phase, a Treatment Phase comprised of 28-day treatment cycles that will continue until disease progression or ...

Phase

0.0 miles

Learn More »

EVOLVE Short DAPT Study

The primary objective of the EVOLVE Short DAPT Study is to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with the SYNERGY Stent System. The study will be conducted up to 120 sites worldwide in the United ...

Phase

0.0 miles

Learn More »